GALNT7
Overview
GALNT7 (Polypeptide N-Acetylgalactosaminyltransferase 7) encodes a UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase involved in O-linked glycosylation. In esophageal adenocarcinoma (EAC), GALNT7 was identified as a fusion partner in an AXIN1-GALNT7 structural rearrangement detected by whole-genome sequencing, implicating O-glycosylation disruption in a subset of EAC.
Alterations observed in the corpus
- Identified as the fusion partner in an AXIN1–GALNT7 fusion detected by whole-genome sequencing in EAC tumor ESO-1060; the fusion was identified in the context of β-catenin-pathway rearrangements in EAC PMID:23525077
Cancer types (linked)
- EAC: Fusion partner (AXIN1-GALNT7) identified by WGS in one EAC tumor; context of β-catenin pathway disruption PMID:23525077
Co-occurrence and mutual exclusivity
- Fusion involves AXIN1, a negative regulator of the WNT/β-catenin pathway; β-catenin pathway mutations (APC, CDH1, AXIN1, CTNNB1) occur in only 9% of EACs PMID:23525077
Therapeutic relevance
- No direct therapeutic targeting reported in the corpus.
Open questions
- Whether the AXIN1-GALNT7 fusion disrupts AXIN1 function (releasing β-catenin) or alters GALNT7 glycosylation activity has not been experimentally determined.
Sources
This page was processed by crosslinker on 2026-05-09.